Stevanato Group S.p.A.
In the published model solve dated 2026-Q2, anchored at $20.22, Stevanato Group S.p.A. (STVN) is priced for +24.4% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 11, 2026 from SEC EDGAR filings.
• Stevanato makes the unglamorous half of the injectable-drug boom, the glass syringes, cartridges, and vials that GLP-1 and biologic therapies ship in, and its premium mix is compounding: high-value solutions grew 17 percent in the first quarter to reach 47 percent of revenue, with GLP-1 products contributing roughly 21 to 22 percent of the total [Source: company Q1 2026 results]. • The biggest specific risk is that the price already assumes the boom: at about 28x company-wide operating income,
Is STVN overvalued? See what's priced in →
133 institutional managers reported holding STVN in 13F filings for the quarter ended 2026-03-31. Together they hold about 16% of the company; the top 10 hold 11%. 30 opened new positions that quarter. Held by Artisan Partners, Morgan Stanley, Invesco, among others. On the short side, 910k shares were sold short as of the 2026-06-15 count, about 0.3% of shares outstanding (2.2 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
STVN's share count grew 8% over the past five years. It pays a dividend, and has paid one every year in our records (7 and counting). Cash returned over the past three years: $47.27M in dividends.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 11, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.